Q1 financial 2025
Category: Press release
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025
AG 2025
Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025
ASCO 2025 curtain
Availability of Transgene’s 2024 Universal Registration Document (URD)
URD 2024
Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations
CTO Appointment
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine – Strong Outlook for 2025
2024 Annual Results
Transgene to Participate in Upcoming Investor Meetings
Investors meetings
Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
Eligibility PEA-PME
Transgene To Participate in the Biomed Forum Investor Conference
BIOMED FORUM
Transgene Announces Financial Calendar for 2025
calendrier 2025